Divi's Labs profit up 80.61 percent to Rs 492.06 crore in Q1
New Delhi: Shares of Divi's Laboratories on Monday rallied over 18 per cent after the company reported 80.61 per cent rise in consolidated net profit for June quarter 2020. The stock jumped 15.93 per cent to a one-year high of Rs 3,228.05 on the BSE.
On the NSE, it gained 18.24 per cent to a 52-week high of Rs 3,293.
The drug firm on Saturday reported 80.61 per cent rise in consolidated net profit at Rs 492.06 crore for June quarter 2020 mainly on account of robust sales.
The company had logged a profit of Rs 272.44 crore in the year-ago same period, Divi's Laboratories said in a filing to BSE.
Total income of the company stood at Rs 1,747.80 crore dring the quarter under review as against Rs 1,193.20 crore in April-June 2019-20, it added.
"The company has been able to have near normal operations during the quarter and there was minimal impact due to COVID-19 pandemic," Divi's Laboratories said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.